Bank of New York Mellon Corp decreased its stake in AVITA Medical, Inc. (NASDAQ:RCEL – Free Report) by 32.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 72,689 shares of the company’s stock after selling 34,919 shares during the quarter. Bank of New York Mellon Corp owned 0.28% of AVITA Medical worth $576,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of RCEL. Silvercrest Asset Management Group LLC purchased a new stake in AVITA Medical during the first quarter valued at about $3,874,000. Hussman Strategic Advisors Inc. purchased a new stake in shares of AVITA Medical in the 1st quarter valued at approximately $673,000. CenterBook Partners LP acquired a new position in AVITA Medical in the 4th quarter worth approximately $234,000. Aigen Investment Management LP purchased a new position in AVITA Medical during the 4th quarter worth approximately $220,000. Finally, Vanguard Group Inc. raised its stake in AVITA Medical by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,408,136 shares of the company’s stock valued at $22,572,000 after purchasing an additional 15,356 shares during the period. Hedge funds and other institutional investors own 27.66% of the company’s stock.
AVITA Medical Price Performance
Shares of RCEL opened at $10.56 on Tuesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 5.29 and a quick ratio of 4.81. The company has a market capitalization of $272.45 million, a price-to-earnings ratio of -6.00 and a beta of 1.54. The business’s 50-day moving average is $9.46 and its 200-day moving average is $10.15. AVITA Medical, Inc. has a fifty-two week low of $7.51 and a fifty-two week high of $18.93.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of AVITA Medical in a research report on Friday, August 9th.
Check Out Our Latest Analysis on RCEL
About AVITA Medical
AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
Featured Articles
- Five stocks we like better than AVITA Medical
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- The Average 401k Balance by Age Explained
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding RCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVITA Medical, Inc. (NASDAQ:RCEL – Free Report).
Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.